Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies
#1413
Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.
Aim(s): To assess EVE efficacy according to prior therapies in patients (pts) with advanced NETs from daily clinical practice.
Materials and methods: Retrospective analysis on pts with advanced G1-G2 NETs treated with EVE in 10 Spanish University hospitals between June-2009 and June-2015.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Custodio A
Authors: Custodio A, Alonso V, Jimenez-Fonseca P, Lopez C, Alonso T,
Keywords: everolimus, previous therapies,
To read the full abstract, please log into your ENETS Member account.